FDA approves new labeling for ViroPharma's Vancocin

Label includes new clinical trial data

EXTON, Pa. — ViroPharma has received approval for updated labeling to its antibiotic drug.

The drug maker announced that the Food and Drug Administration approved the "modernization" of labeling for Vancocin (vancomycin hydrochloride) capsules. The new label includes clinical safety and efficacy data for the drug in treatment strains of Clostridium difficile bacteria currency circulating.

"This new label provides physicians a better understanding about how to treat and monitor patients suffering from the serious and often life-threatening infections that require oral Vancocin therapy," ViroPharma president and CEO Vincent Milano said.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

Login or Register to post a comment.